### Q1. Which feature of Adela's presentation carries the strongest prognostic implications for treatment response and safety monitoring? A) Anxious distress specifier B) Panic attacks specifier C) Mixed features specifier D) Atypical features specifier E) Melancholic features specifier **Correct: A** **ACGME: PC | ABPN: C.V Differential Diagnosis** **Why A:** Adela's worry about finances and aging parents, muscle tension, sleep disruption, and difficulty concentrating represent at least 2 of 5 anxious distress symptoms superimposed on MDD. The anxious distress specifier appears in ~53% of MDD presentations (Fava et al., 2008, American Journal of Psychiatry) and carries elevated suicide risk, worse treatment outcomes (greater symptom severity at baseline), and increased cardiovascular risk (OR=2.1) (Almas et al., 2015, PLoS ONE). Recognizing this specifier affects pharmacotherapy selection (SSRIs/SNRIs preferred over bupropion), psychotherapy choice, and follow-up vigilance for suicidality. **Why B is wrong:** While Adela could develop panic attacks, she does not currently describe spontaneous panic episodes, only worry and physiological tension. Panic attacks specifier requires recurrent, unexpected panic attacks. Her presentation is better captured by the anxious distress specifier, which directly influences SSRI selection. **Why C is wrong:** Mixed features specifier requires simultaneous presence of manic or hypomanic symptoms (elevated mood, decreased need for sleep, increased goal-directed activity, racing thoughts, inflated self-esteem). Adela's anhedonia, guilt, and suicidal ideation are purely depressive; no mania is described. Anxious distress is the operative specifier here. **Why D is wrong:** Atypical features (increased appetite, hypersomnia, leaden paralysis, interpersonal rejection sensitivity) do not fit her presentation. Adela has sleep fragmentation (not hypersomnia) and anhedonia (not hyperphagia). Her anxiety-depression picture is better captured by anxious distress. **Why E is wrong:** Melancholic features (anhedonia, early morning awakening, psychomotor changes, guilt, worse mood in morning) could apply to her anhedonia, but they do not capture the defining feature: anxiety with its associated suicide risk, CV mortality risk, and treatment implications. Anxious distress is both more specific and more clinically actionable. ---

### Q5. Why might Finn's CBT for anxiety be failing, and what does this pattern suggest? A) Severity exceeds CBT capacity B) ADHD blocks CBT skill encoding C) Insufficient CBT duration D) ADHD protects against anxiety E) Inadequate therapist training **Correct: B** **ACGME: PC | ABPN: C.IV Comorbidity** **Why B:** The core distinction between ADHD-Inattentive inattention and anxiety-induced inattention is essential: ADHD inattention is pervasive, trait-based, and present across all contexts (school, home, therapy), while anxiety-induced inattention is state-dependent and situational (worse during specific triggers) (CADDRA, 2020). Finn's inattention during CBT sessions and failure to apply skills outside the office suggests ADHD-level executive function impairment, not anxiety-driven distraction. Untreated ADHD executive dysfunction (working memory, sustained attention, inhibitory control) directly impairs the cognitive load required to learn and apply CBT skills (self-monitoring, thought records, behavioral planning) (Halldorsdottir et al., 2015, Journal of Clinical Child and Adolescent Psychology). Stimulants improve attention, allowing CBT encoding and generalization. **Why A is wrong:** Finn's anxiety severity is not stated as treatment-resistant or severe enough to contraindicate CBT; rather, the *mechanism* of failure is ADHD-related attention impairment, not anxiety intensity. Eight sessions is within expected timeline for early CBT response; the issue is not dose but substrate. **Why C is wrong:** Delaying ADHD assessment in the presence of clear inattentive symptoms wastes time and unnecessarily prolongs anxiety treatment failure. AACAP, AAP, and CADDRA guidelines recommend identifying and treating the most impairing condition first, which in Finn's case is ADHD (his inattention is blocking all learning modalities). Sequencing assessment before treatment is appropriate; delaying assessment prolongs suffering. **Why D is wrong:** Comorbid ADHD is not protective; rather, it is a known negative prognostic factor for CBT response. The CAMS trial (Walkup et al., 2008) subsample analysis by Halldorsdottir et al., 2015, showed ADHD predicted poorer CBT response in children with anxiety. ADHD is a complication, not a protective factor. **Why E is wrong:** While therapist competence matters, the clinical pattern (inattention during session, failure to generalize outside session) points to Finn's neurobiological capacity, not therapist skill. Attributing this to therapist training ignores the documented role of ADHD as a CBT response moderator and delays appropriate treatment. ---

### Q9. Which clinical feature in Moira's presentation is most suggestive of a diagnostic reconsideration? A) Persistent high GAD-7 B) Rumination about decisions C) Intrusive mental rituals D) 18-month treatment failure E) No external compulsions **Correct: C** **ACGME: PC | ABPN: C.V Differential Diagnosis** **Why C:** Moira's description of "going over things in her head," experiencing intrusion and unwantedness, and reporting temporary relief following the mental ritual is the hallmark of mental compulsions, not generalized worry. GAD rumination is open-ended problem-solving ("If I made a mistake with my finances, what could happen?"), whereas OCD mental compulsions are closed, rigid, repetitive rituals aimed at neutralizing a specific, feared obsession ("Did I make a catastrophic error? I must review the decision until I am certain I didn't."). Williams et al. documented that "pure OCD" (mental compulsions without overt behavioral compulsions) is associated with greater severity and lower functioning than previously recognized. The ego-dystonic quality (intrusive, against her will) and the temporary relief pattern are diagnostic for OCD, not GAD. This distinction directly explains her SSRI treatment failure: sertraline 100 mg is adequate for GAD (target 100-150 mg) but insufficient for OCD (which requires 80%+ serotonin transporter occupancy). (Williams et al., 2011, Comprehensive Psychiatry) **Why A is wrong:** A high GAD-7 score alone does not suggest diagnostic reconsideration; it reflects inadequate symptom control. However, the GAD-7 was designed for GAD, not OCD. Its specificity for OCD is limited. The failure to improve despite adequate GAD dosing, combined with the *content* of her symptoms (intrusive, ritual-like, relief-providing), suggests misdiagnosis, not inadequate dose. **Why B is wrong:** Rumination about past decisions occurs in both GAD and OCD. The distinguishing feature is not the *content* (decisions, safety) but the *pattern*: open-ended worry (GAD) versus closed, repetitive mental rituals (OCD). Moira's description of ritualistic review "to make sure" suggests OCD structure, not GAD rumination. **Why D is wrong:** While 18-month treatment failure warrants reassessment, duration alone does not point to a specific alternative diagnosis. GAD, OCD, and other anxiety disorders can be chronic. The *type* of failure (SSRI-responsive diagnoses should show GAD improvement at 100 mg over 18 months) hints at misdiagnosis, but the diagnostic clue is not duration; it is the mental compulsion pattern. **Why E is wrong:** Absence of external compulsions does not rule out OCD. "Pure OCD" (mental compulsions without visible rituals) is well-documented and represents a substantial proportion of OCD presentations. If a clinician equates OCD with visible hand-washing or checking, mental compulsions go unrecognized. This option represents a common diagnostic blind spot, not a valid reason to exclude OCD. ---

### Q13. Which clinical question best distinguishes PTSD from trauma-exacerbated panic disorder in Gideon's case? A) Temporal onset B) Pre-trauma panic history C) Avoidance intentionality D) Spontaneous vs cued attacks E) Nightmare frequency **Correct: D** **ACGME: PC | ABPN: C.V Differential Diagnosis** **Why D:** The key differential hinges on the trigger pattern of panic attacks. In PTSD, panic attacks are cued by trauma reminders. In primary panic disorder, attacks are largely uncued (spontaneous, arising without clear precipitant) (APA, 2022, DSM-5-TR). Gideon's description includes *both* cued (trauma reminders) and uncued ("out of nowhere") attacks. The question is whether the spontaneous attacks represent comorbid panic disorder or are secondary to PTSD hyperarousal. The clinical import is treatment sequencing: if PTSD is primary (panic is a symptom of hyperarousal), treating PTSD first (trauma-focused therapy) will improve panic. If panic disorder is primary, panic-specific interventions may take precedence. In most PTSD + panic comorbidity, PTSD is primary, and VA/DoD 2023 guidelines recommend PTSD-focused treatment (Prolonged Exposure, CPT, EMDR) rather than panic-focused CBT (VA/DoD, 2023). The trigger pattern helps clarify this hierarchy. **Why A is wrong:** Temporal onset (trauma before panic) does not clarify the current functional relationship. Many anxiety disorders follow trauma, but the current maintenance mechanisms (PTSD hyperarousal vs. panic-specific threat monitoring) are what drive treatment sequencing, not historical onset. **Why C is wrong:** Intentionality of avoidance is not the discriminating feature. Both PTSD and panic disorder involve avoidance; the mechanism differs, but both are intentional (goal-directed, anxiety-reducing). **Why B is wrong:** Pre-trauma history of panic would strengthen a comorbid panic disorder diagnosis but is not essential to the current diagnostic question. The current trigger pattern (cued vs. uncued) in the post-trauma context is more clinically actionable. **Why E is wrong:** Nightmare frequency reflects PTSD severity but does not differentiate PTSD from panic disorder. Both disorders can include nightmares in the presence of trauma exposure. ---

### Q16. Tanya's cardiologist clears her cardiovascularly but notes elevated blood pressure and metabolic markers. What does the evidence say about anxiety and independent cardiovascular risk? A) No independent CV effect B) Behavioral pathways only C) Anxiety is CV-protective D) 52% independent CVD increase E) Panic disorder only **Correct: D** **ACGME: MK | ABPN: C.II Predisposing, Protective, and Risk Factors** **Why D:** A meta-analysis by Batelaan et al., 2016 (Depress Anxiety) found that anxiety disorders increase cardiovascular disease (CVD) incidence by 52% (HR = 1.52), independent of depression. The mechanisms are biological, not merely behavioral: chronic autonomic dysregulation (sympathetic overdrive, reduced heart rate variability), sustained inflammatory activation (elevated IL-6, TNF-alpha, CRP), and HPA axis overactivation (chronic cortisol elevation driving metabolic syndrome). Tanya's elevated blood pressure and borderline glucose are consistent with this pathway. Her anxiety is not just causing subjective distress; it is an independent, modifiable risk factor accelerating her cardiometabolic trajectory. Roest et al., 2010 (JACC) confirmed a similar relationship specifically for coronary heart disease events. Treating her anxiety aggressively is a cardiovascular intervention, not just a psychiatric one. **Why A is wrong:** Batelaan et al. specifically adjusted for depression and found that anxiety's cardiovascular effect persists independently (HR = 1.52 after controlling for depressive symptoms). This is a common assumption that the data refutes. Depression and anxiety each carry independent cardiovascular risk through partially overlapping but distinct pathways. **Why B is wrong:** While behavioral pathways (smoking, sedentary lifestyle, poor diet) contribute to cardiovascular risk in anxious populations, the biological mechanisms are independent of behavioral mediators. Tanya does not smoke and drinks only socially, yet her metabolic markers are abnormal. The autonomic-inflammatory-HPA axis pathway operates regardless of health behaviors. **Why C is wrong:** Heightened health awareness is not protective against cardiovascular events. While anxious patients may seek medical care more frequently, the chronic physiological hyperarousal that defines pathological anxiety accelerates rather than prevents cardiovascular disease. Awareness does not offset the biological damage of sustained sympathetic activation. **Why E is wrong:** The Batelaan meta-analysis included GAD, panic disorder, social anxiety disorder, and PTSD. The cardiovascular risk was not limited to panic disorder. GAD's chronic low-grade hyperarousal may actually sustain cardiovascular damage more persistently than panic disorder's episodic surges, though both carry independent risk. ---

### Q20. Hana's obstetrician screens for depression using the Edinburgh Postnatal Depression Scale (EPDS) and the result is negative. Should anxiety screening stop here? A) EPDS captures both B) EPDS anxiety items suffice C) Add GAD-7 separately D) Replace EPDS with PHQ-9 E) Structured diagnostic interview **Correct: C** **ACGME: SBP | ABPN: D.V Diagnostic Assessments and Rating Scales** **Why C:** Perinatal anxiety disorders are more prevalent than perinatal depression. Fawcett et al. found that approximately 1 in 5 women (20.7%) meet criteria for at least one anxiety disorder during the peripartum period, substantially higher than the commonly cited perinatal depression prevalence of approximately 12%. The EPDS was designed to screen for depression; while it contains three anxiety items, its sensitivity for anxiety disorders is insufficient. ACOG and perinatal mental health guidelines increasingly recommend administering the GAD-7 alongside the EPDS to capture the full spectrum of peripartum psychiatric morbidity. Hana's negative EPDS does not rule out clinically significant anxiety, and her GAD-7 of 18 confirms severe anxiety requiring intervention. (Fawcett et al., 2019, Journal of Affective Disorders) **Why A is wrong:** The EPDS includes three items addressing worry and panic, but these do not substitute for a validated anxiety-specific measure. The EPDS's primary psychometric validation was for depression detection. Its anxiety items have lower sensitivity and specificity for anxiety disorders compared to the GAD-7. Relying on the EPDS alone misses a substantial proportion of perinatal anxiety. **Why B is wrong:** The EPDS anxiety items were not independently validated as an anxiety screener. Their sensitivity for detecting anxiety disorders is lower than the GAD-7. "Sufficient" overstates their diagnostic utility for anxiety-specific assessment. Separate anxiety screening is warranted given the 20.7% perinatal prevalence (Fawcett et al., 2019, Journal of Clinical Psychiatry). **Why D is wrong:** Replacing the EPDS with the PHQ-9 would swap one depression measure for another without adding anxiety screening. The PHQ-9 is a depression screener with no anxiety-specific content. The correct approach is to add the GAD-7 alongside the EPDS, not to replace one depression tool with another. **Why E is wrong:** While structured diagnostic interviews (SCID-5, MINI) provide gold-standard diagnosis, self-report screeners (GAD-7, EPDS) are validated, practical, and appropriate for routine perinatal screening. Requiring a structured interview for every patient would create an access barrier. The GAD-7's sensitivity (89%) and specificity (82%) for GAD make it an effective first-line screening tool (Spitzer et al., 2006, Archives of Internal Medicine). ---

### Q24. Earl's presentation illustrates a common pattern in geriatric anxiety. What is the primary reason anxiety disorders are under-recognized in older adults? A) Prevalence declines after 65 B) Patient resistance C) Age-identical presentation D) Cognitive screens detect anxiety E) Somatic predominance, aging normalization **Correct: E** **ACGME: MK | ABPN: C.III Clinical Presentation, Symptoms, and Signs** **Why E:** Anxiety is the most common psychiatric condition in older adults, with global prevalence of clinically significant anxiety symptoms at approximately 28% (Shafiee et al., 2024). Under-recognition is driven by a convergence of patient-side and provider-side factors. Patient-side: older adults present primarily with somatic complaints (insomnia, chronic pain, dizziness, fatigue, GI distress) rather than cognitive worry, and they normalize fear and avoidance as expected consequences of aging ("I'm just getting old"). Provider-side: diagnostic nihilism ("anxiety is normal at his age") and attribution of anxiety symptoms to medical comorbidities or cognitive decline. Earl demonstrates both patterns: somatic-dominant presentation (insomnia, pain, dizziness) and self-attribution to aging. His checking behaviors and driving avoidance are anxiety manifestations, not depression or cognitive decline. **Why A is wrong:** Anxiety prevalence does not decline after 65. Approximately 28% of older adults have clinically significant symptoms (Shafiee et al., 2024, Journal of General and Family Medicine). While new-onset panic disorder may decrease, GAD, specific phobias, and anxiety related to health and loss increase or persist. The under-recognition creates an illusion of lower prevalence. **Why B is wrong:** While stigma exists across age groups, "resistance to evaluation" is not the primary barrier to recognition. Many older adults, like Earl, present to primary care repeatedly with somatic complaints. They are willing to discuss their symptoms but frame them somatically rather than psychologically. The barrier is presentation style and provider attribution, not patient refusal. **Why C is wrong:** Geriatric anxiety presents differently from younger adults. Older adults emphasize somatic symptoms (pain, dizziness, fatigue) over cognitive worry, and are more likely to normalize symptoms as aging. This age-specific presentation is precisely why under-recognition occurs: clinicians expecting younger-adult anxiety presentations miss the geriatric pattern. **Why D is wrong:** Cognitive screening tools (MMSE, MoCA) assess cognitive function, not anxiety. They cannot detect anxiety disorders and were not designed to do so. A normal MoCA does not rule out anxiety. Relying on cognitive screening for psychiatric evaluation misses the target entirely. ---

### Q28. Felix's escitalopram has been effective for anxiety, but insomnia persists. What does this pattern suggest? A) Inadequate escitalopram dose B) Discontinue escitalopram C) Medication-induced insomnia D) Insomnia never responds to anxiolytics E) Independent comorbid insomnia **Correct: E** **ACGME: MK | ABPN: C.IV Comorbidity** **Why E:** The DSM-5 and International Classification of Sleep Disorders, Third Edition (ICSD-3) formally abandoned the concept of "secondary insomnia." Insomnia is now understood as a frequently independent disorder that can be comorbid with, triggered by, but not merely a symptom of anxiety. Belleville et al., 2010 (Behav Res Ther) demonstrated that anxiety-focused CBT produces robust improvements in anxiety but only modest improvements in comorbid insomnia. Residual insomnia maintains physiological hyperarousal (elevated cortisol, sympathetic tone), sustains rumination, and significantly increases anxiety relapse risk. Felix illustrates this: his anxiety responded to escitalopram (GAD-7 = 8), but his insomnia persists because the perpetuating factors (conditioned arousal to the bed, clock-watching, weekend napping, phone checking) are now self-sustaining, independent of the original anxiety trigger. **Why A is wrong:** Felix's GAD-7 is 8 (mild), indicating good anxiety response on escitalopram 15 mg. Attributing his insomnia to undertreated anxiety ignores the objective evidence of adequate anxiety control. The "insomnia is always a symptom" framework is outdated (pre-DSM-5 "secondary insomnia" concept) and would lead to unnecessary SSRI dose escalation without addressing the actual perpetuating factors. **Why C is wrong:** SSRIs (including escitalopram) can cause insomnia as a side effect, typically presenting as difficulty staying asleep or vivid dreams. However, Felix's insomnia pattern (sleep-onset difficulty with pre-sleep rumination and maladaptive behaviors) is characteristic of chronic insomnia disorder, not medication-induced sleep disruption. His insomnia predated escitalopram response and has persisted despite anxiety improvement, suggesting it is comorbid rather than iatrogenic. **Why D is wrong:** "Never" is too absolute. Some patients' insomnia does improve substantially when anxiety is treated, particularly when insomnia was primarily driven by anxious arousal. The accurate statement is that anxiety treatment alone often produces only modest insomnia improvement in comorbid presentations, not that it never works. **Why B is wrong:** Discontinuing an effective anxiolytic because one comorbid condition persists would sacrifice his anxiety gains without addressing the insomnia. The correct approach is to treat the insomnia as a separate comorbid condition while continuing escitalopram. Stopping it risks anxiety relapse. ---

### Q32. Lorraine's multi-system somatic complaints with normal workups most strongly suggest which diagnostic consideration? A) Anxiety with somatic amplification B) Malingering C) Rare autoimmune condition D) Conversion disorder E) Illness anxiety disorder **Correct: A** **ACGME: PC | ABPN: C.V Differential Diagnosis** **Why A:** Lorraine's presentation has four positive indicators for anxiety-driven somatic symptoms (Module 6, Section 9.6): (1) symptoms vary with emotional state (worsen during parent-teacher conferences, improve during summer), (2) symptoms involve multiple organ systems simultaneously (chest, neurological, GI, musculoskeletal, headache), (3) extensive medical workups have been unrevealing across all five specialist evaluations, and (4) symptoms worsen with attention and stressful contexts. This pattern is characteristic of anxiety disorder manifesting through somatic amplification: physiological hyperarousal (sympathetic activation) produces real sensations (chest tightness, dizziness, paresthesias, GI distress) that are then catastrophically misinterpreted, driving further medical help-seeking (Greenberg et al., 1999, Journal of Clinical Psychiatry). **Why B is wrong:** Malingering involves intentional symptom fabrication for external gain (financial compensation, avoiding work, legal benefit). Lorraine is a working teacher who continues to perform her job; there is no identified secondary gain. Her symptoms vary with genuine emotional stress, suggesting authentic anxiety-driven physiology, not fabrication. Malingering is rare and should not be the default explanation for unexplained somatic symptoms. **Why C is wrong:** While rare conditions should remain on the differential, Lorraine has been evaluated by five specialists over 18 months with consistently normal results. The pattern (multi-system, stress-responsive, improving with reduced demands) is more consistent with anxiety than autoimmune disease. Red flags (new neurological deficits, weight loss, fever, progressive symptoms) are absent. Continuing to pursue rare diagnoses without considering anxiety perpetuates the cycle of unrevealing workups. **Why D is wrong:** Conversion disorder (Functional Neurological Symptom Disorder) involves neurological symptoms (weakness, paralysis, seizures, sensory loss) inconsistent with recognized neurological conditions. Lorraine's symptoms (chest pain, dizziness, GI distress, headaches) are diffuse somatic complaints across multiple systems, not focal neurological deficits. **Why E is wrong:** Recommending "further medical testing" perpetuates the cycle of repeated workups that has already failed to provide relief or diagnosis over 18 months. Illness Anxiety Disorder involves preoccupation with illness with minimal somatic symptoms. Lorraine has prominent multi-system somatic symptoms better explained by an underlying anxiety disorder. ---